Related references
Note: Only part of the references are listed.BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
V. Dunnett-Kane et al.
ANNALS OF ONCOLOGY (2020)
Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage
Siddharth De et al.
CELL REPORTS (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Disentangling Pro-mitotic Signaling during Cell Cycle Progression using Time-Resolved Single-Cell Imaging
Manuela Benary et al.
CELL REPORTS (2020)
Signaling diversity enabled by Rap1-regulated plasma membrane ERK with distinct temporal dynamics
Jeremiah Keyes et al.
ELIFE (2020)
A Live-Cell Screen for Altered Erk Dynamics Reveals Principles of Proliferative Control
Alexander G. Goglia et al.
CELL SYSTEMS (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
Joao M. Fernandes Neto et al.
NATURE COMMUNICATIONS (2020)
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Irem Ozkan-Dagliyan et al.
CELL REPORTS (2020)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ras-Mediated Activation of the Raf Family K nases
Elizabeth M. Terrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma
Grace P. Leung et al.
MOLECULAR CANCER RESEARCH (2019)
Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer
Galia Maik-Rachline et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Chih-Shia Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium
Raphael Brandt et al.
NATURE COMMUNICATIONS (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
Sarbajeet Nagdas et al.
CELL REPORTS (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha et al.
CANCER DISCOVERY (2019)
Metabolic signatures of cancer cells and stem cells
Andrew M. Intlekofer et al.
NATURE METABOLISM (2019)
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Aayoung Hong et al.
CANCER DISCOVERY (2018)
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
Manuel Sanclemente et al.
CANCER CELL (2018)
ERK regulates mitochondrial membrane potential in fission deficient Drosophila follicle cells during differentiation
Darshika Tomer et al.
DEVELOPMENTAL BIOLOGY (2018)
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
Andrea M. Gross et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen et al.
CANCER CELL (2018)
Genetically Encoded Fluorescent Biosensors Illuminate the Spatiotemporal Regulation of Signaling Networks
Eric C. Greenwald et al.
CHEMICAL REVIEWS (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation
J-Ming Yang et al.
NATURE COMMUNICATIONS (2018)
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni et al.
ELIFE (2018)
Fast Dynamic in vivo Monitoring of Erk Activity at Single Cell Resolution in DREKA Zebrafish
Vanessa Mayr et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
A compendium of ERK targets
Evrim B. Uenal et al.
FEBS LETTERS (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK
Peter Kubiniok et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Xiangjun Kong et al.
NATURE (2017)
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Yaohua Xue et al.
NATURE MEDICINE (2017)
Linear Integration of ERK Activity Predominates over Persistence Detection in Fra-1 Regulation
Taryn E. Gillies et al.
CELL SYSTEMS (2017)
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant et al.
PLOS ONE (2017)
A Real-Time Biosensor for ERK Activity Reveals Signaling Dynamics during C. elegans Cell Fate Specification
Claire de la Cova et al.
DEVELOPMENTAL CELL (2017)
Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
J. Cisowski et al.
ONCOGENE (2016)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
The Emerging Hallmarks of Cancer Metabolism
Natalya N. Pavlova et al.
CELL METABOLISM (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles
Ehud Wainstein et al.
CURRENT OPINION IN CELL BIOLOGY (2016)
Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms
Florian Gnad et al.
PROTEOMICS (2016)
Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation
Anastasia Mylona et al.
SCIENCE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Roser Busca et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
Akiyoshi Kasuga et al.
INVESTIGATIONAL NEW DRUGS (2015)
Receptor Level Mechanisms Are Required for Epidermal Growth Factor (EGF)-stimulated Extracellular Signal-regulated Kinase (ERK) Activity Pulses
Breanne Sparta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells
Scott A. Stuart et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Mohammad Atefi et al.
MOLECULAR CANCER (2015)
Mitochondrial Division Is Requisite to RAS-Induced Transformation and Targeted by Oncogenic MAPK Pathway Inhibitors
Madhavika N. Serasinghe et al.
MOLECULAR CELL (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ERK reinforces actin polymerization to power persistent edge protrusion during motility
Michelle C. Mendoza et al.
SCIENCE SIGNALING (2015)
The nuclear translocation of ERK1/2 as an anticancer target
Alexander Plotnikov et al.
NATURE COMMUNICATIONS (2015)
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
Arun M. Unni et al.
ELIFE (2015)
ERK reinforces actin polymerization to power persistent edge protrusion during motility
Michelle C. Mendoza et al.
SCIENCE SIGNALING (2015)
Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma
Robert Parker et al.
FRONTIERS IN ONCOLOGY (2015)
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Brinda Alagesan et al.
CLINICAL CANCER RESEARCH (2015)
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2015)
Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Melissa R. Junttila et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Novel Reporter for Faithful Monitoring of ERK2 Dynamics in Living Cells and Model Organisms
Francois Sipieter et al.
PLOS ONE (2015)
Targeting RAS-mutant Cancers: Is ERK the Key?
Meagan B. Ryan et al.
TRENDS IN CANCER (2015)
High-Sensitivity Measurements of Multiple Kinase Activities in Live Single Cells
Sergi Regot et al.
CELL (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Identification of Extracellular Signal-regulated Kinase 1 (ERK1) Direct Substrates using Stable Isotope Labeled Kinase Assay-Linked Phosphoproteomics
Liang Xue et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition
Robert Parker et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Optimization of ERK Activity Biosensors for both Ratiometric and Lifetime FRET Measurements
Pauline Vandame et al.
SENSORS (2014)
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
Simona Lamba et al.
CELL REPORTS (2014)
Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals
John G. Albeck et al.
MOLECULAR CELL (2013)
Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions
Mathieu Courcelles et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Cosimo Commisso et al.
NATURE (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
A Versatile Toolkit to Produce Sensitive FRET Biosensors to Visualize Signaling in Time and Space
Rafael D. Fritz et al.
SCIENCE SIGNALING (2013)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS
Matthew P. Stokes et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
A Two-Dimensional ERK-AKT Signaling Code for an NGF-Triggered Cell-Fate Decision
Jia-Yun Chen et al.
MOLECULAR CELL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2011)
Spatiotemporally Regulated Protein Kinase A Activity Is a Critical Regulator of Growth Factor-Stimulated Extracellular Signal-Regulated Kinase Signaling in PC12 Cells
Katie J. Herbst et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Development of an optimized backbone of FRET biosensors for kinases and GTPases
Naoki Komatsu et al.
MOLECULAR BIOLOGY OF THE CELL (2011)
Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals
Yaara Zwang et al.
MOLECULAR CELL (2011)
ERK-MAPK Drives Lamellipodia Protrusion by Activating the WAVE2 Regulatory Complex
Michelle C. Mendoza et al.
MOLECULAR CELL (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Large-Scale Discovery of ERK2 Substrates Identifies ERK-Mediated Transcriptional Regulation by ETV3
Scott M. Carlson et al.
SCIENCE SIGNALING (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Gene ontology analysis for RNA-seq: accounting for selection bias
Matthew D. Young et al.
GENOME BIOLOGY (2010)
Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics
Cuiping Pan et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
Functional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in Melanoma
William M. Old et al.
MOLECULAR CELL (2009)
Rapid and sustained nuclear-cytoplasmic ERK oscillations induced by epidermal growth factor
Harish Shankaran et al.
MOLECULAR SYSTEMS BIOLOGY (2009)
Cell fate decisions are specified by the dynamic ERK interactome
Alex von Kriegsheim et al.
NATURE CELL BIOLOGY (2009)
Phosphoproteomics reveals new ERK MAP kinase targets and links ERK to nucleoporin-mediated nuclear transport
Hidetaka Kosako et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
Christine A. Pratilas et al.
CANCER RESEARCH (2008)
Active Ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis
Jean H. Overmeyer et al.
MOLECULAR CANCER RESEARCH (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer
Jihane Basbous et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate
Silvia D. M. Santos et al.
NATURE CELL BIOLOGY (2007)
Continuous ERK activation downregulates anti proliferative genes throughout G1 phase to allow cell-cycle progression
Takuya Yamamoto et al.
CURRENT BIOLOGY (2006)
ERK1c regulates Golgi fragmentation during mitosis
YD Shaul et al.
JOURNAL OF CELL BIOLOGY (2006)
The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity
M Ebisuya et al.
JOURNAL OF CELL SCIENCE (2005)
Role of glycogen synthase kinase 3β in rapamycin-mediated cell cycle regulation and chemosensitivity
JJ Dong et al.
CANCER RESEARCH (2005)
Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry
T Lee et al.
MOLECULAR CELL (2004)
Sef is a spatial regulator for Ras/MAP kinase signaling
S Torii et al.
DEVELOPMENTAL CELL (2004)
A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration
LO Murphy et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Ras pathway signaling on endomembranes
TG Bivona et al.
CURRENT OPINION IN CELL BIOLOGY (2003)
Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D
M Schmidt et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues
DA Fantz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mitotic phosphorylation of Golgi reassembly stacking protein 55 by mitogen-activated protein kinase ERK2
SA Jesch et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission
AJ Bardwell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions
T Tanoue et al.
EMBO JOURNAL (2001)
Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry
TS Lewis et al.
MOLECULAR CELL (2000)
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
R Sears et al.
GENES & DEVELOPMENT (2000)
A conserved docking motif in MAP kinases common to substrates, activators and regulators
T Tanoue et al.
NATURE CELL BIOLOGY (2000)
Share Paper
